{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:42:15Z","timestamp":1791175335892,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T00:00:00Z","timestamp":1417219200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s00259-014-2941-1","type":"journal-article","created":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T13:37:45Z","timestamp":1417441065000},"page":"377-385","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Prognostic impact of 18F-FDG PET\/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer"],"prefix":"10.1007","volume":"42","author":[{"given":"D.","family":"Groheux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Giacchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Delord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"de Roquancourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Merlet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. S.","family":"Hamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Espi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Hindi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,29]]},"reference":[{"key":"2941_CR1","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1200\/JCO.2008.17.1496","volume":"26","author":"D Fuster","year":"2008","unstructured":"Fuster D, Duch J, Paredes P, Velasco M, Mu\u00f1oz M, Santamar\u00eda G, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography\/computed tomography compared with conventional imaging procedures. J Clin Oncol. 2008;26:4746\u201351.","journal-title":"J Clin Oncol"},{"key":"2941_CR2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10549-011-1767-9","volume":"131","author":"BB Koolen","year":"2012","unstructured":"Koolen BB, Vrancken Peeters MJ, Aukema TS, Vogel WV, Oldenburg HS, van der Hage JA, et al. 18F-FDG PET\/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques. Breast Cancer Res Treat. 2012;131:117\u201326.","journal-title":"Breast Cancer Res Treat"},{"key":"2941_CR3","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/djs451","volume":"104","author":"D Groheux","year":"2012","unstructured":"Groheux D, Hindi\u00e9 E, Delord M, Giacchetti S, Hamy AS, de Bazelaire C, et al. Prognostic impact of 18FDG-PET-CT findings in clinical stage III and IIB breast cancer. J Natl Cancer Inst. 2012;104:1879\u201387.","journal-title":"J Natl Cancer Inst"},{"key":"2941_CR4","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s00259-013-2595-4","volume":"41","author":"A Cochet","year":"2014","unstructured":"Cochet A, Dygai-Cochet I, Riedinger JM, Humbert O, Berriolo-Riedinger A, Toubeau M, et al. (18)F-FDG PET\/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations. Eur J Nucl Med Mol Imaging. 2014;41:428\u201337.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2941_CR5","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938\u201348.","journal-title":"N Engl J Med"},{"key":"2941_CR6","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1002\/cncr.27581","volume":"118","author":"NU Lin","year":"2012","unstructured":"Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012;118:5463\u201372.","journal-title":"Cancer"},{"key":"2941_CR7","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","volume":"13","author":"LA Carey","year":"2007","unstructured":"Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329\u201334.","journal-title":"Clin Cancer Res"},{"key":"2941_CR8","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","volume":"26","author":"C Liedtke","year":"2008","unstructured":"Liedtke C, Mazouni C, Hess KR, Andr\u00e9 F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275\u201381.","journal-title":"J Clin Oncol"},{"key":"2941_CR9","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G Minckwitz von","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796\u2013804.","journal-title":"J Clin Oncol"},{"key":"2941_CR10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164\u201372. doi: 10.1016\/S0140-6736(13)62422-8 .","journal-title":"Lancet"},{"key":"2941_CR11","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/bjc.2014.81","volume":"110","author":"S Giacchetti","year":"2014","unstructured":"Giacchetti S, Porcher R, Lehmann-Che J, Hamy AS, de Roquancourt A, Cuvier C, et al. Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide\/anthracycline neoadjuvant regimen. Br J Cancer. 2014;110:1413\u20139.","journal-title":"Br J Cancer"},{"key":"2941_CR12","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00259-010-1640-9","volume":"38","author":"D Groheux","year":"2011","unstructured":"Groheux D, Giacchetti S, Moretti JL, Porcher R, Espi\u00e9 M, Lehmann-Che J, et al. Correlation of high (18)F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426\u201335.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2941_CR13","doi-asserted-by":"crossref","first-page":"R78","DOI":"10.1186\/bcr3472","volume":"15","author":"J Choi","year":"2013","unstructured":"Choi J, Kim DH, Jung WH, Koo JS. Metabolic interaction between cancer cells and stromal cells according to breast cancer molecular subtype. Breast Cancer Res. 2013;15:R78.","journal-title":"Breast Cancer Res"},{"key":"2941_CR14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1634\/theoncologist.2012-0397","volume":"18","author":"A Prat","year":"2013","unstructured":"Prat A, Adamo B, Cheang MCU, Anders CK, Carey LA, Perou CM. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist. 2013;18:123\u201333.","journal-title":"Oncologist"},{"key":"2941_CR15","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1158\/1078-0432.CCR-13-0799","volume":"19","author":"H Masuda","year":"2013","unstructured":"Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19:5533\u201340.","journal-title":"Clin Cancer Res"},{"key":"2941_CR16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.breast.2011.12.011","volume":"21","author":"T Nagao","year":"2012","unstructured":"Nagao T, Kinoshita T, Hojo T, Tsuda H, Tamura K, Fujiwara Y. The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics. Breast. 2012;21:289\u201395.","journal-title":"Breast"},{"key":"2941_CR17","doi-asserted-by":"crossref","first-page":"219869","DOI":"10.1155\/2013\/219869","volume":"2013","author":"FO Ademuyiwa","year":"2013","unstructured":"Ademuyiwa FO, Ellis MJ, Ma CX. Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer. J Oncol. 2013;2013:219869.","journal-title":"J Oncol"},{"key":"2941_CR18","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1093\/annonc\/mdt361","volume":"24","author":"B Gerber","year":"2013","unstructured":"Gerber B, Loibl S, Eidtmann H, Rezai M, Fasching PA, Tesch H, et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol. 2013;24:2978\u201384.","journal-title":"Ann Oncol"},{"key":"2941_CR19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2967\/jnumed.111.094045","volume":"53","author":"D Groheux","year":"2012","unstructured":"Groheux D, Hindi\u00e9 E, Giacchetti S, Delord M, Hamy AS, de Roquancourt A, et al. Triple-negative breast cancer: early assessment with 18F-FDG PET\/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse. J Nucl Med. 2012;53:249\u201354.","journal-title":"J Nucl Med"},{"key":"2941_CR20","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.ejca.2014.04.020","volume":"50","author":"D Groheux","year":"2014","unstructured":"Groheux D, Hindi\u00e9 E, Giacchetti S, Hamy AS, Berger F, Merlet P, et al. Early assessment with (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer. Eur J Cancer. 2014;50:1864\u201371.","journal-title":"Eur J Cancer"},{"key":"2941_CR21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00259-010-1626-7","volume":"38","author":"L Evangelista","year":"2011","unstructured":"Evangelista L, Baretta Z, Vinante L, Cervino AR, Gregianin M, Ghiotto C, et al. Tumour markers and FDG PET\/CT for prediction of disease relapse in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:293\u2013301.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2941_CR22","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/cncr.25727","volume":"117","author":"L Champion","year":"2011","unstructured":"Champion L, Brain E, Giraudet A, Le Stanc E, Wartski M, Edeline V, et al. Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET\/CT imaging and impact on patient management. Cancer. 2011;117:1621\u20139.","journal-title":"Cancer"},{"key":"2941_CR23","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00432-009-0746-6","volume":"136","author":"L Pan","year":"2010","unstructured":"Pan L, Han Y, Sun X, Liu J, Gang H. FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis. J Cancer Res Clin Oncol. 2010;136:1007\u201322.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2941_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta14500","volume":"14","author":"M Pennant","year":"2010","unstructured":"Pennant M, Takwoingi Y, Pennant L, Davenport C, Fry-Smith A, Eisinga A, et al. A systematic review of positron emission tomography (PET) and positron emission tomography\/computed tomography (PET\/CT) for the diagnosis of breast cancer recurrence. Health Technol Assess. 2010;14:1\u2013103.","journal-title":"Health Technol Assess"},{"key":"2941_CR25","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1148\/radiol.12110853","volume":"266","author":"D Groheux","year":"2013","unstructured":"Groheux D, Espi\u00e9 M, Giacchetti S, Hindi\u00e9 E. Performance of FDG PET\/CT in the clinical management of breast cancer. Radiology. 2013;266:388\u2013405.","journal-title":"Radiology"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-014-2941-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-014-2941-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-014-2941-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T16:06:22Z","timestamp":1558713982000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-014-2941-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,29]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["2941"],"URL":"https:\/\/doi.org\/10.1007\/s00259-014-2941-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,29]]}}}